KwaZulu-Natal HIV and TB clinical trials unit
Official title: KwaZulu-Natal Clinical Trials Unit
Funded at Centre/aids Programme/res/south Africa · NIH-11229783 · Data updated 2026-11-12
This program runs clinical trials in KwaZulu-Natal to test new HIV prevention tools, vaccines, and treatments for people at risk of or living with HIV and tuberculosis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centre/aids Programme/res/south Africa NIH-funded |
| Lab location | 1 site (Durban, SOUTH AFRICA) |
| Project start | March 1, 2007 |
| Project end | November 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,882,055 |
| NIH project number | 5UM1AI069469-20 |
| Project ID | NIH-11229783 on NIH RePORTER |
Who could benefit from this research
✓Could help
People in and around Durban who are at risk for HIV or tuberculosis, adolescents and adults eligible under specific trial rules, or people living with HIV who meet trial criteria.
✕Less likely to help
People who are not at risk for HIV/TB, live far from the KZN clinical sites, are outside the studied age groups, or who do not meet individual trial inclusion criteria are unlikely to benefit directly.
What this research studies
This unit brings together several established research clinics in Durban to run multiple clinical trials focused on HIV and tuberculosis. The combined sites have enrolled thousands of participants and maintain high retention while working with experienced investigators and research staff. Trials include prevention technologies such as vaccines and antibodies as well as treatment and co-treatment strategies for HIV and TB. If you visit one of the participating clinics you may be invited to join a specific trial that fits your health situation.
Why it matters
Potential benefit: If successful, this program could speed access to better HIV prevention and treatment options and help reduce infections and deaths in the region.
How similar studies have gone: Previous trials run by this unit and partner networks have led to major successes such as tenofovir-based PrEP and improved HIV–TB co-treatment strategies, showing this approach can change care.
Where this research is happening
-
Centre/aids Programme/res/south Africa
Durban, South Africa Active
Researchers
- Principal investigator: Abdool Karim, Quarraisha — Centre/aids Programme/res/south Africa
- Study coordinator: Abdool Karim, Quarraisha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.